Cannabotech Ltd. (CNTC.TA)

Cannabotech Ltd. (CNTC.TA) — VMCI valuation read

Headline read on CNTC.TA: VMCI of 41/100 versus a Healthcare sector median of 50. The 9-point below-median position is what makes Cannabotech Ltd. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on CNTC.TA: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on CNTC.TA: value (CNTC.TA trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 0.8x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

CNTC.TA rose 1.4% over the trailing 7 days, with a -13.2% read on a 30-day basis.